1. Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies 
Jay B. Wish, MD, Daniel W. Coyne, MD 
Mayo Clinic Proceedings 
Volume 82, Issue 11, Pages (November 2007)
DOI: /
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

2. FIGURE 1
Initiation of anemia management in patients with CKD. CBC = complete blood cell count; CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; RBC = red blood cell.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

3. FIGURE 2
Recommended ESA treatment in patients with CKD. CKD = chronic kidney disease; ESA = erythropoiesis-stimulating agent; GI= gastrointestinal; Hb= hemoglobin; IV = intravenous; SC = subcutaneous.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions

4. FIGURE 3
Recommended iron therapy for patients with CKD who are receiving erythropoiesis-stimulating agents. SI conversion factor, to convert serum ferritin level to pmol, multiply by CHr = reticulocyte hemoglobin content; CKD = chronic kidney disease; IV = intravenous.
Mayo Clinic Proceedings  , DOI: ( / )
Copyright © 2007 Mayo Foundation for Medical Education and Research Terms and Conditions